Celltrion Inc
068270
Company Profile
Business description
Founded in 2002 in South Korea, Celltrion is one of the largest biosimilar manufacturers around the world. Biosimilar drug sales accounted for 87% of its total revenue in 2024. Europe is the largest market for its biosimilar drug sales, contributing more than 47% of its total revenue, followed by 37% from the North America region and 16% from emerging markets. Besides biosimilar manufacturing, Celltrion entered the contract manufacturing business in 2024.
Contact
13-6 SongDo-Dong
Yeonsu-gu
Incheon City406-840
KORT: +82 32855000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,916
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,393.00 | 19.30 | 0.21% |
| CAC 40 | 8,206.07 | 17.48 | 0.21% |
| DAX 40 | 24,258.80 | 427.81 | 1.80% |
| Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
| FTSE 100 | 9,403.57 | 49.00 | 0.52% |
| HKSE | 25,858.83 | 611.73 | 2.42% |
| NASDAQ | 22,990.54 | 310.57 | 1.37% |
| Nikkei 225 | 49,648.61 | 463.11 | 0.94% |
| NZX 50 Index | 13,324.48 | 20.48 | -0.15% |
| S&P 500 | 6,735.13 | 71.12 | 1.07% |
| S&P/ASX 200 | 9,091.50 | 15.60 | 0.17% |
| SSE Composite Index | 3,863.89 | 24.14 | 0.63% |